New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCerebrolysin vs Semaglutide

Cerebrolysin vs Semaglutide

Side-by-side comparison of key properties, dosing, and research.

Cognitive EnhancementAnti-Aging & Longevity
Cerebrolysin
GLP-1 / Weight Loss Agonists
Semaglutide
Summary
Cerebrolysin is a porcine brain-derived neuropeptide complex that mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, NT-3). It promotes neurogenesis, neuroprotection, and synaptic plasticity, and is approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease.
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
Half-Life
Variable for the complex; individual peptide fractions: minutes to hours
~7 days
Admin Route
IV, IM
SubQ, Oral
Research
Typical Dose
5–10 mL
0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
Frequency
Daily for 10–20 days
Once weekly, subcutaneous
Key Benefits
  • Promotes neurogenesis and synaptic plasticity
  • Approved for stroke rehabilitation (accelerates recovery)
  • Alzheimer's disease: slows progression and improves cognition
  • Traumatic brain injury recovery
  • Enhances memory and executive function
  • Neuroprotection against oxidative stress and excitotoxicity
  • Anti-amyloid and anti-tau effects
  • Mood improvement and reduced anxiety
  • Average 15–20% body weight reduction in clinical trials (STEP trials)
  • Significant reduction in appetite and food cravings
  • Improvement in blood sugar control and insulin sensitivity
  • Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
  • May reduce risk of kidney disease
  • Improves metabolic markers (cholesterol, blood pressure)
  • FDA-approved — extensively studied with robust safety data
  • Weekly dosing convenience
Side Effects
  • Generally well tolerated
  • Mild nausea and dizziness (IV infusion)
  • Headache at initiation
  • Rare: agitation (usually at very high doses)
  • +2 more
  • Nausea (most common, especially during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal discomfort
  • +4 more
Stacks With